Methylation levels in 697 brain samples from ROSMAP participants and 301 blood samples from ADNI participants were independently compared between AD cases and controls in the total sample, and within APOE ε4 carrier and non-carrier subgroups (Fig. 1a and Supplementary Table 1). This evidence concerns the gene APOE and Alzheimer disease.